Aidoc, the leading provider of AI healthcare solutions, has announced a collaboration with Temple Health ("Temple") to integrate the Aidoc AI Care Platform to reduce cost of care. The Aidoc AI solutions, implemented across the health system's facilities, target the cardiovascular, neurosciences, and radiology service lines to optimize clinical operations by identifying more appropriate patients in need of interventions; streamlining communication across critical care teams; prioritizing patients with suspected urgent medical conditions and helping shorten the length of stay for patients in the health system's hospitals. An American Hospital Association report from April revealed 33% of hospitals have been operating on negative margins, with average patient length of stays (an average cost of over $2,000 per patient, per day) growing by just under 10% and healthcare worker shortages driving up labor costs by 20%. Health systems are turning to technologies like AI to help boost operational efficiency, sustain high quality of care and cut costs. Aidoc's medical imaging AI solutions showed they could help reduce hospital patient length of stay by 1.3 days for patients suffering brain bleeds and 2.07 days for patients suffering lung blood clots.

This is my new AI in Healthcare Highlights & Milestones Report for Summer 2022. This report includes an overview of advances made during the summer across the healthcare spectrum including important studies, regulatory clearances, fundraising, partnerships, and growth in the AI ecosystem worldwide. This summer scientists demonstrated how they successfully used AI in many areas including: to reduce sepsis deaths, to predict cardiac events, to detect breast cancer, to detect lung cancer, to detects osteoporosis, to detect Parkinson's, to monitor diabetic retinopathy, to detect heart disease, to detect bladder cancer, to enable pathology, to detect fractures, and to monitor Parkinson's using the Apple Watch. In July scientists in Germany published a large scale study demonstrating that radiologists working with AI were more accurate detecting breast cancer than radiologists working without AI, and vice versa - the AI was more accurate when working with a radiologist than when working independently. The study was led by Vara, a German company, in collaboration with radiologists at the Essen University Hospital in Germany and the Memorial Sloan Kettering Cancer Center in New York. Vara's AI is has been used by radiologists in German breast screening centers for two years and is used in 30% of Germany's breast cancer screening centers. Vara's AI software is also used to screen for breast cancer in a hospital in Mexico and in a hospital in Greece.

This week Aidoc announced that they have raised $110 million in their Series D expansion round. This round of funding was co-led by TCV and Alpha Intelligence Capital with participation from CDIB Capital. Funding raised in this round will go toward expansion of Aidoc's first of its kind AI Care Platform. The platform offers health systems a singular platform solution designed to help doctors manage the entire patient lifecycle--from diagnostic aid, to consultation, to suggested treatment paths, to patient follow-up tools. In clinical studies, this platform has proven to reduce turnaround time, shorten patient length of stay and improve patient outcomes.

This partnership will help health systems address the increasing volume of medical images and the worldwide radiologist labor shortage. Integration of Boneview into Aidoc's AI platform will give many more clinicians access to a tool to help them identify fractures in limbs, pelvis, thoracic and lumbar spine, and rib cage. Aidoc's end-to-end AI platform already includes numerous third-party AI vendors including Imbio, Riverain, Subtle, Icometrix and ScreenPoint. Over 152 million X-rays are performed every year in the US. Although there are about 37,000 radiologists in the US, they are not evenly distributed.

Could a new artificial intelligence (AI)-enabled advance have an impact in the diagnosis and treatment of brain aneurysms? The Food and Drug Administration (FDA) has granted 510(k) clearance to Aidoc's new AI platform for brain aneurysms. In addition to identifying and triaging suspected cases, the algorithm facilitates communication and workflow between radiologists, neurologists and neuroendovascular surgeons, according to the company. Researchers have estimated that approximately 6.5 million people in the United States have an unruptured brain aneurysm.1 The Brain Aneurysm Foundation has noted that most aneurysms are small, ranging from 1/8 inch to an inch, and ruptured aneurysms are reportedly misdiagnosed or there is a delay in diagnosis in 25 percent of patients who present to health-care providers.1 Elad Walach, the CEO and co-founder of Aidoc, said the new AI-enabled algorithm may help enhance timely diagnosis and care for brain aneurysms.

Aidoc, the leading provider of healthcare AI solutions, today announced that it received FDA 510(k) clearance for its triage and notification of pneumothorax on X-ray exams. A one-stop partner for the enterprise's clinical AI needs, Aidoc's other seven FDA-cleared solutions are already implemented across U.S. health systems, flagging and communicating suspected pathologies in CT exams – and now have expanded to the high volume X-ray modality. Aidoc's newly FDA-cleared solution runs on all X-ray machines including portable ones, and is designed to analyze X-ray images. It automatically flags positive cases of pneumothorax, facilitating physicians to read X-rays in a timely manner. The ability to quickly identify pneumothorax is imperative as it can worsen rapidly and result in respiratory or cardiac failure.

Aidoc, a provider of artificial intelligence (AI) solutions for medical imaging, has announced a $66 million investment, bringing its total funding to $140 million. This Series C round, led by General Catalyst, follows a surge in demand for Aidoc's AI-driven solutions, including the largest clinical deployment of AI in healthcare through its partnership with Radiology Partners. Aidoc co-founder and CEO Elad Walach, said: "This investment comes after significant milestones; expanding our product lines, doubling our FDA clearances and quadrupling our customer base. We are experiencing a huge expansion, which is also a direct result of C-level executives adopting an AI strategy and integrating our platform as a must-have solution across clinical pathways. It is truly rewarding – and a great responsibility – to be the trusted partner of the most innovative health systems and physician practices across the globe." A pioneer in healthcare AI, Aidoc's FDA-cleared solutions analyse medical images for critical conditions and trigger actionable alerts directly in the imaging workflow supporting medical specialists in reducing turnaround time and improving quality of care.

Aidoc announced today that the US Food and Drug Administration (FDA) has given regulatory clearance for the commercial use of its triaging and notification algorithms for flagging and communicating incidental pulmonary embolism . Flagging incidental, critical findings is a huge technical challenge due to the varied imaging protocols used and lower incidences of such cases. The ability to prioritize incidental critical conditions accurately is a breakthrough in the value AI can bring to the radiologist workflow. "The most common use case we experienced is for critical unsuspected findings in oncology surveillance patients" said Dr. Cindy Kallman, Chief, Section of CT at Cedars-Sinai Medical Center. "The ability to call the referring physician while the patient is still in the house is huge. We are essentially offering a point-of-care diagnosis of PE for our outpatients. Our referring physicians have been completely wowed by this."

Catching abnormalities on a medical image is important, but case backlogs often mean radiologists are cut short on how long they can spend with each one. Enter Aidoc, a 4-year-old Israel-based startup providing artificial intelligence tools for radiologists. The company secured an additional $20 million for its Series B funding led by Square Peg Capital, which initially led the round that began in April 2019. The new funds bring the Series B round to $47 million and gives Aidoc a total of $60 million raised to date, according to Crunchbase data. If the AI detects something, the tools alert the radiologist, Aidoc co-founder and CEO Elad Walach told Crunchbase News. "What has happened in recent history is that scanners have become cheaper, so now there is more imaging, which is overloading a radiologist's workflow," he said.

Aidoc, which bills itself as an AI solutions provider for radiologists, today closed a $20 million extension to the series B it raised in April 2019, bringing the round total to $47 million and the company's total raised to $60 million. Cofounder and CEO Elad Walach says the money will be used to support new customers after revenue tripled from the beginning of 2020. Computer vision holds promise for the $6.5 trillion medical diagnostics industry, as highlighted by a 2018 paper in the journal Nature that found that some algorithms can identify skin cancer as accurately as a panel of doctors. For instance, Sight Diagnostics uses machine learning algorithms to perform point-of-care complete blood count (CBC) tests within 10 minutes with no more than a pinprick of blood. Aidoc got its start in 2016, when veterans of the Israeli Defense Force put their heads together to create an AI platform targeting certain health care verticals.